Bayer Seeks Kerendia Label Expansion in Non-Diabetic CKD – October 8, 2026
Key Takeaways Bayer’s Kerendia sNDA gains FDA acceptance for CKD patients without diabetes.Kerendia significantly delayed kidney disease progression…
#Germany #DE #Europe #EU #Europa #Bayer #financial #financialplanning #investing #Investment #investmentadvice #onlineinvestment #onlinestocktrading #onlinetrading #quote #quotes #stock #stockmarket #stockquotes #stocks
https://www.europesays.com/germany/105727/